BMO Capital Markets’s $600 target on VRTX

VRTX Vertex Pharmaceuticals

$515 → $600 (+17%) by Sep 2027

Outperform · reiterates · said Sep 22, 2026 · 12-month default horizon

Open: judged on the close on Sep 22, 2027

The article this target came from

BMO reiterates Vertex stock rating on positive trial data

Investing.com · Sep 22, 2026

BMO Capital reiterated an Outperform rating and $600.00 price target on Vertex Pharmaceuticals Inc.

BMO Capital Markets’s track record → Vertex Pharmaceuticals →

A fact about what BMO Capital Markets published, as reported by Investing.com, not a recommendation from Dalsna Finance; BMO Capital Markets is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.